July 13, 2020

The Niche

Knoepfler lab stem cell blog

Month: June 2015

4 min read

Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly some of them may have been more hopes than predictions. At mid-year today on June 30th, how am I doing with 2015 predictions? See below. Note that of course for some the jury is still out. BTW, stay tuned for more on an upcoming update …Read More

4 min read

What’s on your mind on this Monday morning and are you caffeinated enough yet? Depending on where you live it may even be time for dinner, bed, or already early Tuesday. Here are some Monday musings… To get safe and effective stem cell treatments to patients in a responsible, compliant manner you need commercial efforts and that in almost all cases means biotechs. Doing this blog for 5+ years has made it really sink in just how crucial the commercial side is to all …Read More

2 min read

The US Congress recently held its first hearing on human germline genetic modification. The meeting included CRISPR-Cas9 pioneer Jennifer Doudna (see video here) on the panel. See image of Cas9 structure from Wikipedia. CRISPR-Cas9 is a powerful, strikingly efficient tool for genetic engineering of cells and whole organisms. Now Republican congressional leaders have included a provision in the current spending bill that would block editing of viable human embryos and could interfere with important research. Concern over a possible reactive move by Congress on …Read More

3 min read

By Heather Main The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical environment is as disastrous as having a great product but no cash to get it past the post. The fruitful interaction of researchers, companies and clinics will save a …Read More